




About Jiksak Bioengineering



Name	Jiksak Bioengineering Inc.
Established	Feb. 7 th , 2017
Founder	Jiro Kawada, PhD
Capital Stock	10 M yen (Cumulative Funds :1 B yen)
Head Office	322, CIBERNICS MEDICAL INNOVATION BASE-A, Tonomachi 3-25-16, Kawasaki-ku, Kawasaki-shi, Kanagawa 210-0821, JAPAN
Staff	Board Members: 3 persons, Employee: 8 persons
Shareholders	ANRI, Cyberdyne Inc., CEJ Capital, Zeon corp. etc





Neuron-selective Drug Delivery







Overview Jiksak Drug Delivery System (DDS)

Jiksak shuttle technology capabilities

- **Neuron-selective Drug Delivery through intravenous injection.**
- Jiksak shuttle's selectivity increases drug concentration in neurons and reduces drug off-targeting to cells leading to adverse reaction reduction
- Versatility to deliver various types of molecules to neurons.

Collaboration Opportunity




- Seeking potential molecules for neuron targeting delivery





Jiksak's Innovation, Neuron Selective Drug Delivery System

1. **Neuron-selective.**
2. **Small molecules, oligonucleotides and biologics delivery to motor axons and cell bodies (and other neurons).**
3. **Administered by systemic injection (IV).**



For internal use

